2026-04-22T02:56:27Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/577852025-03-07T07:29:40Zcom_10324_1179com_10324_931com_10324_894col_10324_1306

Corral Gudino, Luis Cusacovich Torres, Iván Martín González, José Ignacio Muela Molinero, Alberto Abadia Otero, Jesica González Fuentes, Roberto Ruiz de Temiño de la Peña, Ángela Tapia Moral, Elena Cuadrado Medina, Francisca Martín Asenjo, Miguel Miramontes González, José Pablo Delgado González, José Luis Inés, Sandra Abad Manteca, Laura Usátegui Martín, Iciar Ruiz Albi, Tomás Miranda Riaño, Sara Rodríguez Fortúnez, Patricia Rodríguez Jiménez, Consuelo López Franco, Esperanza Marcos, Miguel 2022-12-15T09:51:45Z 2022-12-15T09:51:45Z 2022 European Journal of Clinical Investigation, 2022, vol. 53, n. 1, e13881. 0014-2972 https://uvadoc.uva.es/handle/10324/57785 10.1111/eci.13881 1 European Journal of Clinical Investigation 53 1365-2362 Producción Científica Background: The efficacy and safety of high versus medium doses of glucocorticoids for the treatment of patients with COVID-19 has shown mixed outcomes in controlled trials and observational studies. We aimed to evaluate the effectiveness of methylprednisolone 250 mg bolus versus dexamethasone 6 mg in patients with severe COVID-19. Methods: A randomised, open-label, controlled trial was conducted between February and August 2021 at four hospitals in Spain. The trial was suspended after the first interim analysis since the investigators considered that continuing the trial would be futile. Patients were randomly assigned in a 1:1 ratio to receive dexamethasone 6 mg once daily for up to 10 days or methylprednisolone 250 mg once daily for 3 days. Results: Of the 128 randomised patients, 125 were analysed (mean age 60 ± 17 years; 82 males [66%]). Mortality at 28 days was 4.8% in the 250 mg methylprednisolone group versus 4.8% in the 6 mg dexamethasone group (absolute risk difference, 0.1% [95% CI, −8.8 to 9.1%]; p = 0.98). None of the secondary outcomes (admission to the intensive care unit, non-invasive respiratory or high-flow oxygen support, additional immunosuppressive drugs, or length of stay), or prespecified sensitivity analyses were statistically significant. Hyperglycaemia was more frequent in the methylprednisolone group at 27.0 versus 8.1% (absolute risk difference, −18.9% [95% CI, −31.8 to - 5.6%]; p = 0.007). Conclusions: Among severe but not critical patients with COVID-19, 250 mg/d for 3 days of methylprednisolone compared with 6 mg/d for 10 days of dexamethasone did not result in a decrease in mortality or intubation. application/pdf eng Wiley info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc/4.0/ © 2022 The Author(s) Atribución-NoComercial 4.0 Internacional COVID- 19 Dexamethasone Intubation Intratracheal Methylprednisolone Mortality 32 Ciencias Médicas Effect of intravenous pulses of methylprednisolone 250 mg versus dexamethasone 6 mg in hospitalised adults with severe COVID ‐19 pneumonia: An open‐label randomised trial info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion https://onlinelibrary.wiley.com/doi/full/10.1111/eci.13881 SI